Compare AbCellera Biologics Inc (ABCL) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Global X Autonomous & Electric Vehicles — how do they compare? AbCellera Biologics Inc trades at $9.05 (market cap $2.85B), while Global X Autonomous & Electric Vehicles trades at $35.54. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| ABCL | DRIV | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $42.53 |
52-Week Low | $2.78 | $25.23 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
DRIV trades at $35.78, up 2.55% today, with a bullish technical signal driven by moving averages. The stock shows strong year-to-date performance, supported by positive sentiment in the electric vehicle sector. Key support is at $35, with resistance at $36. Recent news highlights global EV sales growth and China's expanding market ambitions.
Outlook remains positive due to sector tailwinds and autonomous driving advancements, but risks include regulatory pressures and competitive threats from Chinese automakers. Institutional interest is strong, though overbought RSI signals caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
